INSERM U1040, Montpellier, France.
Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.
Genetic abnormalities are common in patients with multiple myeloma, and may deregulate gene products involved in tumor survival, proliferation, metabolism and drug resistance. In particular, translocations may result in a high expression of targeted genes (termed spike expression) in tumor cells. We identified spike genes in multiple myeloma cells of patients with newly-diagnosed myeloma and investigated their prognostic value.
Genes with a spike expression in multiple myeloma cells were picked up using box plot probe set signal distribution and two selection filters.
In a cohort of 206 newly diagnosed patients with multiple myeloma, 2587 genes/expressed sequence tags with a spike expression were identified. Some spike genes were associated with some transcription factors such as MAF or MMSET and with known recurrent translocations as expected. Spike genes were not associated with increased DNA copy number and for a majority of them, involved unknown mechanisms. Of spiked genes, 36.7% clustered significantly in 149 out of 862 documented chromosome (sub)bands, of which 53 had prognostic value (35 bad, 18 good). Their prognostic value was summarized with a spike band score that delineated 23.8% of patients with a poor median overall survival (27.4 months versus not reached, P<0.001) using the training cohort of 206 patients. The spike band score was independent of other gene expression profiling-based risk scores, t(4;14), or del17p in an independent validation cohort of 345 patients.
We present a new approach to identify spike genes and their relationship to patients' survival.
多发性骨髓瘤患者中常见遗传异常,这些异常可能使涉及肿瘤存活、增殖、代谢和耐药性的基因产物失活。特别是易位可能导致肿瘤细胞中靶向基因的高表达(称为尖峰表达)。我们在新诊断的多发性骨髓瘤患者的骨髓瘤细胞中鉴定了尖峰基因,并研究了它们的预后价值。
使用箱线图探针集信号分布和两个选择过滤器从多发性骨髓瘤细胞中挑选出具有尖峰表达的基因。
在 206 例新诊断的多发性骨髓瘤患者队列中,鉴定出 2587 个具有尖峰表达的基因/表达序列标签。一些尖峰基因与一些转录因子(如 MAF 或 MMSET)和已知的复发性易位有关,这是意料之中的。尖峰基因与 DNA 拷贝数增加无关,并且对于大多数基因来说,它们涉及未知的机制。在尖峰基因中,36.7%显著聚类在 862 个记录的染色体(亚)带中的 149 个中,其中 53 个具有预后价值(35 个不良,18 个良好)。使用 206 例患者的训练队列,用尖峰带评分来总结它们的预后价值,该评分将 23.8%的患者划分为中位总生存期较差的患者(27.4 个月与未达到,P<0.001)。在 345 例独立验证队列中,尖峰带评分独立于其他基于基因表达谱的风险评分、t(4;14)或 del17p。
我们提出了一种新的方法来鉴定尖峰基因及其与患者生存的关系。